Skip to content

Fremanezumab

NERVOUS SYSTEM

Also known as: ajovy, fremanezumab (genetical recombination), fremanezumab-vfrm, LBR-101, PF-04472429, RN307, TEV-48125

EMA approvedFDA approvedPMDA approvedATC N02CD03

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Fremanezumab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2018. DrugCentral lists 1 molecular target, including CALCA. Recorded indications include Migraine and Prevention of migraine attacks.

  • Molecular targets: CALCA (1 listed in DrugCentral).
  • Indications: Migraine and Prevention of migraine attacks.
  • ATC code: N02CD03 (Calcitonin gene-related peptide (CGRP) antagonists).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Migraine
  • Prevention of migraine attacks

Mechanism & targets

Molecular targets (1)

TargetGeneActionActivity
Calcitonin gene-related peptide 1CALCAotherKd 10.30

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2021-06-23PMDA—OTSUKA PHARMACEUTICAL Co., Ltd.
2019-03-28EMA—TEVA GMBH
2018-09-14FDA—TEVA PHARMS USA

ATC classification

ATC codeTherapeutic hierarchy
N02CD03NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Calcitonin gene-related peptide (CGRP) antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Injection site erythema456.4
Accidental exposure to product451.7
Injection site pruritus347.4
Injection site rash332.4
Injection site reaction287.5
Injection site swelling285.9
Injection site pain285.7
Device leakage172.7
Migraine169.9
Incorrect dose administered by device146.1
Device malfunction134.7
Drug dose omission by device132.9

Chemical structure

Molecular formula—
Molecular weight—
CAS number1655501-53-3
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Fremanezumab used for?

DrugCentral lists the following indications for Fremanezumab: Migraine and Prevention of migraine attacks.

How does Fremanezumab work?

Its molecular targets in DrugCentral include CALCA.

When was Fremanezumab first approved?

Fremanezumab was first approved by the FDA in 2018.

Browse: all drugs starting with F · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2018-09-14
AgencyFDA
Targets1
Indications2
Formula—
DrugCentral ID5315
Interactive profile